NORTHSTAR ELECTRONICS, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH MAJOR AEROSPACE COMPANY

 Virginia Beach, VA– December 20, 2016- Northstar Electronics, Inc.,(OTCQB:NEIK), the “Company” is pleased to announce that it has signed a Memorandum of Understanding (MOU) with a subsidiary of a major international Aerospace Company.

Northstar Electronics’ subsidiary, Northstar Sealand Enterprises Ltd (NSEL), has the objective of acquiring the exclusive world-wide rights to an enhanced version of a single engine Turbo-Prop industrial airplane from the subsidiary of the international aerospace company.

NSEL would manufacture, market and sell the airplanes and also carry out Maintenance, Repair and Overhaul (MRO). The MOU outlines key actions and goals to be reached in order to implement this new business plan for the Company.

The signing of this MOU is a first step which ultimately should lead to NSEL reaching its manufacturing and marketing goals within a reasonable time period.  As part of the overall new focus of the Company, NSEL would also implement a strong marketing and sales campaign to maximize early orders for the new version of the airplane.

As more information becomes available and further developments occur between Northstar Electronics and the Aerospace Company, shareholders and other interested parties will be promptly notified on the progress in accordance with guidelines and requirements indicative for publicly traded companies.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

 

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

Predictive Technology Group, Inc. (PRED) Retains Stevenson & Company CPAs

Stevenson & Company CPAs will act as independent auditors of Predictive Technology Group, Inc.

Salt Lake City, UT — (December 20, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the Company has retained Stevenson & Company CPAs as its PCAOB auditing firm.

Stevenson & Company CPAs will act as independent auditors as required to become a fully reporting company under US SEC rules.

Upon completion of the audited financial statements and other legal narratives required to become fully reporting, The Company will transmit its registration statement to the US SEC for approval.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. The Company does not undertake any obligation to provide an update with respect to any potential legal or financial transactions, except as required under the applicable law.

 

 

Bravo Multinational Incorporated (BRVO) – Update  

Toronto, Canada – December 19th, 2016- Bravo Multinational Incorporated (OTCQB: BRVO) reports on Company activities.

10Q for Quarter ending September 30, 2016:

The Company would like first to apologize to its shareholders for the yet to be filed “Quarterly Report.” The cause of this extensive delay is due to serious ongoing health issues with BRVO’s CFO. That being said, after numerous interviews with several firms over the past few weeks, the Company has on Friday, December 16, 2016, finalized the engagement of a new accounting firm that will immediately take over the full accounting duties of the Company. This new firm located in New York State has extensive US SEC accounting experience.  Management welcomes the new addition to the Bravo team. The Company’s PCAOB auditing firm, Scrudato & Co., PA-Certified Public Accounting Firm, has not changed.

El Salvador- Central America:

The gaming license operational openings in municipalities in the capital city of San Salvador, El Salvador will be delayed due to current circumstances out of the Company’s control. The parties that were to fund and open the two locations have decided to hold off on the location openings. Bravo’s management has worked with the El Salvadoran associates for the past year to plan this new business venture and hope to have the licenses put to work, shortly.

Equipment Sales:

BRVO sales division for gaming equipment reports that Q4 is moving well within anticipated projections.  Management looks forward to furthering future sales growth going into, and throughout 2017.

OTCQB Status:

The Company has had many inquiries regarding the Company’s OTCQB status due to the late filing and the sub-penny share price. The OTCQB status will be maintained and immediately regained as soon as the filings are up- to- date.  As for the share price, the Company has six months to regain a level of one cent (0.01) to maintain the OTCQB status.

 

Market Stock Selling/buying:

Recently, the Company is aware of certain large shareholders (non-affiliates) that have informed the Company that they have chosen to divest in Bravo at this time to take advantage of year-end tax planning, as well as, to move on to alternate investments. This trading activity resulted in more than 15 million shares being put onto the open market, recently.  Before this occurring, the last couple of weeks the Company feels that significant short selling pressure started in mid-September, adding to the share price declines. The Company has no control over free-trading share sales.

Core Business Focus:

BRVO continues its positive efforts to increase revenues and intends to grow the core gaming equipment business throughout next year and bring forth a strong balance sheet for 2017.  Q4 2016 should report positive sales growth. Additionally, the company has made arrangements to enhance its equipment sales operation, by opening an independent Bravo sales office in the New Year.   Regardless of the current share price, the core business is growing, and BRVO anticipates extensive growth throughout 2017.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with its main focus on the development and expansion of the Casino Gaming Equipment holdings and Gaming related business activities throughout Central and South America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

 

Predictive Technology Group, Inc. (PRED) Announces Notice of US Patent Allowance for Method for Treating Patients with Genetic Spinal Deformities and Syndromes

Allowance Strengthens Commercialization Strategy of Company’s Proprietary Diagnostics and Therapeutics

Salt Lake City, UT — (December 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a fundamental patent application – US20160296671 -that covers the practice of administering “ANY” spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.

“We are pleased to see this latest allowance that supports PRED’s novel approach to diagnosing spinal disorders and syndromes, “said Mike Schramm, PRED’s Director of Intellectual Property. “This allowed US patent application supports the commercial use of both our diagnostic and next-generation companion treatment products.”

The claims of the ‘671 application build on previously issued US patents 8,123,787, 8,641,738, and 9,370,431 to which ‘671 claims priority and further bolster Predictive Technology Group’s Intellectually Property position.

“We are gratified to see this latest application allowance, which covers the core technology underlying the Company’s molecular diagnostic test” said Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, Inc. “Furthermore, this fundamental patent covers not only spinal applications of our technology but establishes a precedent for the other patent applications that have been submitted on the Company’s portfolio of next-generation diagnostic and companion treatment products.”

The allowance of this new application is a significant milestone for Predictive Technology Group.  The patent establishes the foundation of key intellectual property (IP) covering ANY treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker.  This newly allowed application is additive to previously announced patents.  Furthermore, the Company has additional US and International patent applications pending and will pursue such applications with the objective of receiving additional issued patents in additional disease states.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases, www.predictivetechnologygroup.com

For more information about PRED, contact Mr. Richard Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.